Perkins Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Perkins Capital Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$414K	Sell	7,180 -250	-3%	-$14.4K	0.31%	57
2026 Q1	$451K	Sell	7,430 -1,000	-12%	-$58.3K	0.42%	57
2025 Q4	$455K	Hold	8,430	–	–	0.36%	61
2025 Q3	$380K	Sell	8,430 -2,000	-19%	-$93.4K	0.34%	61
2025 Q2	$483K	Sell	10,430 -2,300	-18%	-$113K	0.49%	52
2025 Q1	$776K	Sell	12,730 -495	-4%	-$28.9K	0.82%	40
2024 Q4	$748K	Sell	13,225 -1,266	-9%	-$70.7K	0.66%	45
2024 Q3	$750K	Sell	14,491 -2,500	-15%	-$117K	0.7%	43
2024 Q2	$706K	Buy	16,991 +350	+2%	+$15.7K	0.67%	44
2024 Q1	$902K	Hold	16,641	–	–	0.75%	43
2023 Q4	$854K	Buy	16,641 +1,000	+6%	+$52.5K	0.73%	43
2023 Q3	$908K	Hold	15,641	–	–	0.9%	36
2023 Q2	$1M	Hold	15,641	–	–	0.87%	39
2023 Q1	$1.08M	Hold	15,641	–	–	1.02%	38
2022 Q4	$1.13M	Hold	15,641	–	–	1.19%	31
2022 Q3	$1.11M	Sell	15,641 -867	-5%	-$62.9K	1.24%	29
2022 Q2	$1.27M	Hold	16,508	–	–	1.32%	26
2022 Q1	$1.21M	Hold	16,508	–	–	0.99%	42
2021 Q4	$1.03M	Buy	16,508 +58	+0.4%	+$3.4K	0.69%	51
2021 Q3	$973K	Hold	16,450	–	–	0.6%	50
2021 Q2	$1.1M	Hold	16,450	–	–	0.62%	49
2021 Q1	$1.04M	Hold	16,450	–	–	0.6%	50
2020 Q4	$1.02M	Sell	16,450 -300	-2%	-$18.4K	0.67%	45
2020 Q3	$1.01M	Buy	+16,750	New	+$1.01M	0.93%	36
2020 Q1	$941K	Sell	16,875 -300	-2%	-$18.3K	1.14%	32
2019 Q4	$1.1M	Sell	17,175 -1,550	-8%	-$88.8K	0.99%	34
2019 Q3	$950K	Sell	18,725 -150	-0.8%	-$7.05K	0.82%	49
2019 Q2	$856K	Buy	18,875 +6,000	+47%	+$279K	0.6%	49
2019 Q1	$614K	Sell	12,875 -3,250	-20%	-$162K	0.4%	76
2018 Q4	$838K	Sell	16,125 -2,375	-13%	-$128K	0.65%	48
2018 Q3	$1.15M	Sell	18,500 -500	-3%	-$29.7K	0.69%	48
2018 Q2	$1.05M	Sell	19,000 -2,125	-10%	-$115K	0.75%	45
2018 Q1	$1.34M	Buy	21,125 +950	+5%	+$61.1K	1.2%	22
2017 Q4	$1.24M	Buy	20,175 +2,650	+15%	+$166K	1.19%	23
2017 Q3	$1.12M	Buy	+17,525	New	+$1.02M	1.17%	26
2017 Q1	–	Sell	-8,125	Closed	-$475K	–	112
2016 Q4	$475K	Hold	8,125	–	–	0.52%	67
2016 Q3	$438K	Buy	8,125 +2,500	+44%	+$161K	0.44%	73
2016 Q2	$414K	Buy	+5,625	New	+$397K	0.47%	64

Other funds holding BMY

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

FWIA

Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

DLA

Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

ETC

Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Perkins Capital Management's BMY Position: Q2 2026 in Review

Perkins Capital Management reduced its Bristol-Myers Squibb (BMY) stake by 3.4% in Q2 2026, selling an estimated $14.4K and leaving 7,180 shares worth $414K. The position accounts for 0.31% of the portfolio, ranked #57.

Perkins Capital Management first reported a position in BMY in Q2 2016 and has held it in 38 quarters since. The position peaked at $1.34M in Q1 2018. 879 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Perkins Capital Management held 7,180 shares of Bristol-Myers Squibb worth $414K as of Q2 2026.
Perkins Capital Management sold 250 Bristol-Myers Squibb shares in Q2 2026, an estimated $14.4K.
Bristol-Myers Squibb made up 0.31% of Perkins Capital Management's portfolio in Q2 2026, its #57 holding.
Perkins Capital Management first reported a position in Bristol-Myers Squibb in Q2 2016 and has held it in 38 quarters since.
Perkins Capital Management's Bristol-Myers Squibb position peaked at $1.34M in Q1 2018.
879 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Perkins Capital Management's 13F filing for Q2 2026, filed 24 Jul 2026.